Genomics to select treatment for patients with metastatic breast cancer.

Breast Neoplasms / drug therapy Clinical Decision-Making / methods DNA Mutational Analysis Disease Progression Female Genes, BRCA1 Genes, BRCA2 Genome, Human / genetics Genomics Humans Neoplasm Metastasis / drug therapy Phthalazines / therapeutic use Piperazines / therapeutic use

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
10 2022

Historique:

received: 24 10 2021

accepted: 03 07 2022

pubmed: 8 9 2022

medline: 15 10 2022

entrez: 7 9 2022

Statut: ppublish

Résumé

Cancer progression is driven in part by genomic alterations

Identifiants

DOI: 10.1038/s41586-022-05068-3 PMID: 36071165

pubmed: 36071165

doi: 10.1038/s41586-022-05068-3

pii: 10.1038/s41586-022-05068-3

doi:

Substances chimiques

Phthalazines 0

Piperazines 0

olaparib WOH1JD9AR8

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

Pagination

343-348

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell. 144, 646–674 (2011).

doi: 10.1016/j.cell.2011.02.013 pubmed: 21376230

Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 173, 400–416 (2018).

doi: 10.1016/j.cell.2018.02.052 pubmed: 29625055 pmcid: 6066282

Yates, L. R. et al. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Ann. Oncol. 29, 30–35 (2018).

doi: 10.1093/annonc/mdx707 pubmed: 29140430

Arnedos, M. et al. Precision medicine for metastatic breast cancer—limitations and solutions. Nat. Rev. Clin. Oncol. 12, 693–704 (2015).

doi: 10.1038/nrclinonc.2015.123 pubmed: 26196250

Gennari, A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475–1495 (2021).

doi: 10.1016/j.annonc.2021.09.019 pubmed: 34678411

Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895–1902 (2018).

doi: 10.1093/annonc/mdy263 pubmed: 30137196 pmcid: 6158764

André, F. et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 15, 267–274 (2014).

doi: 10.1016/S1470-2045(13)70611-9 pubmed: 24508104

Massard, C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 7, 586–595 (2017).

doi: 10.1158/2159-8290.CD-16-1396 pubmed: 28365644

Mosele, F. et al. Recommendations for the use of next generation sequencing in patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann. Oncol. 31, 1491–1505 (2020).

doi: 10.1016/j.annonc.2020.07.014 pubmed: 32853681

Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324–1334 (2015).

doi: 10.1016/S1470-2045(15)00188-6 pubmed: 26342236

Kingston, B. et al. Exceptional response to AKT inhibition in patients with breast cancer and germline PTEN mutations. JCO Precis. Oncol. 3, PO.19.00130 (2019).

pubmed: 32923864 pmcid: 7446515

Taniguchi, C. M. et al. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res. 70, 5305–5315 (2010).

doi: 10.1158/0008-5472.CAN-09-3399 pubmed: 20530665 pmcid: 3204358

Curtis, C. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).

doi: 10.1038/nature10983 pubmed: 22522925 pmcid: 3440846

Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4–23 (2017).

doi: 10.1016/j.jmoldx.2016.10.002 pubmed: 27993330 pmcid: 5707196

Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017).

Johnson, A. et al. Clinical use of precision oncology decision support. JCO Precis. Oncol. 2017, PO.17.00036 (2017).

Hyman, D. M., Taylor, B. S. & Baselga, J. Implementing genome-driven oncology. Cell. 168, 584–599 (2017).

doi: 10.1016/j.cell.2016.12.015 pubmed: 28187282 pmcid: 5463457

Costello, J. C. et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat. Biotechnol. 32, 1202–1212 (2014).

doi: 10.1038/nbt.2877 pubmed: 24880487 pmcid: 4547623

Tuveson, D. & Clevers, H. Cancer modeling meets human organoid technology. Science 364, 952–955 (2019).

doi: 10.1126/science.aaw6985 pubmed: 31171691

Lee, S. H. et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 173, 515–528 (2018).

doi: 10.1016/j.cell.2018.03.017 pubmed: 29625057 pmcid: 5890941

Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523–533 (2017).

doi: 10.1056/NEJMoa1706450 pubmed: 28578601

Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189–194 (2018).

doi: 10.1038/nature25475 pubmed: 29420467 pmcid: 5808581

Bachelot, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat. Med. 27, 250–255 (2021).

doi: 10.1038/s41591-020-01189-2 pubmed: 33462450

Commo, F. et al. rCGH: a comprehensive array-based genomic profile platform for precision medicine. Bioinformatics 32, 1402–1404 (2016).

doi: 10.1093/bioinformatics/btv718 pubmed: 26708336

Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017).

doi: 10.1038/nm.4292 pubmed: 28288110 pmcid: 5833945

Telli, M. L. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22, 3764–3773 (2016).

doi: 10.1158/1078-0432.CCR-15-2477 pubmed: 26957554 pmcid: 6773427

Carene, D. et al. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. Breast Cancer Res. Treat. 179, 387–401 (2020).

doi: 10.1007/s10549-019-05462-y pubmed: 31620934

Condorelli R et al, Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 30, 365–373 (2019)

Tung NM et al, TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J. Clin. Oncol. 38, 4274–4282 (2020)